Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,208,443.70. The trade was a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total value of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.80, for a total value of $854,400.00.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX opened at $84.86 on Monday. The firm has a 50 day simple moving average of $92.63 and a 200 day simple moving average of $93.22. Vaxcyte, Inc. has a 52 week low of $53.83 and a 52 week high of $121.06. The company has a market cap of $10.58 billion, a PE ratio of -18.45 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the firm posted ($0.91) EPS. On average, equities analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Analysts Set New Price Targets

PCVX has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective on the stock. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average price target of $145.71.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock worth $252,000 after purchasing an additional 110 shares during the last quarter. CIBC Asset Management Inc increased its position in Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after purchasing an additional 110 shares during the last quarter. Amalgamated Bank raised its stake in shares of Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock worth $284,000 after purchasing an additional 150 shares in the last quarter. Finally, Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter valued at about $27,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.